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Abstract
 
Alveolar macrophages (AMs) express the class A scavenger receptor macrophage receptor with
collagenous structure (MARCO), but its role in vivo in lung defense against bacteria and envi-
ronmental particles has not been studied. We used MARCO-deficient mice to directly test the
in vivo role of AM MARCO in innate defense against pneumococcal infection and environ-
mental particles. In a murine model of pneumococcal pneumonia, MARCO
 
   
 
 mice displayed
an impaired ability to clear bacteria from the lungs, increased pulmonary inflammation and
cytokine release, and diminished survival. In vitro binding of 
 
Streptococcus pneumoniae
 
 and in
vivo uptake of unopsonized particles by MARCO
 
   
 
 
 
AMs were dramatically impaired.
MARCO
 
   
 
 mice treated with the “inert” environmental particle TiO
 
2
 
 showed enhanced
inflammation and chemokine expression, indicating that MARCO-mediated clearance of inert
particles by AMs prevents inflammatory responses otherwise initiated by other lung cells. Our
findings point to an important role of MARCO in mounting an efficient and appropriately
regulated innate immune response against inhaled particles and airborne pathogens.
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Introduction
 
Lung macrophages are both sentinels and the first line of
defense against infection or injury from inhaled agents. The
repertoire of receptors expressed on the alveolar macro-
phage (AM) surface is critical for binding, uptake, and re-
sponse to microbes and inhaled unopsonized environmental
particles. One family of receptors likely to be important for
normal host defense of the lung are the class A macrophage
scavenger receptors (SRAs). This designation describes a
group of pattern recognition receptors composed of three
members as follows: SRA-I/II, macrophage receptor with
collagenous structure (MARCO; reference 1), and the re-
cently  identified SRCL (scavenger receptor with C-type
lectin; reference 2). All are multifunctional trimeric glyco-
proteins expressed primarily by macrophages.
The class A scavenger receptors (especially the relatively
well-studied SRA-I/II) have been implicated to varying
degrees in systemic innate immunity against infection (3–
10). Other data also suggest the potential involvement of
MARCO in antibacterial defense mechanisms. For example,
constitutive MARCO is up-regulated in liver and spleen
macrophages after bacterial infection (11–13). Moreover,
MARCO can bind LPS or LTA (14), as well as intact bacteria
(
 
Escherichia coli
 
 and 
 
Staphylococcus aureus
 
; references 15, 16).
MARCO is also expressed on dendritic cells (17) and may
play a role in adaptive immunity. We have previously iden-
tified MARCO as a major receptor on AMs for in vitro
binding of unopsonized environmental particles and certain
microorganisms (15, 18), but its actual functional importance
for lung host defense in vivo has not been investigated. Use
of mice with genetic deletion of MARCO allowed specific
analysis of its in vivo role in defense of the lung against two
commonly encountered challenges, pneumococcal bacteria
and inert environmental dusts.
 
Address correspondence to Lester Kobzik, Physiology Program, Harvard
School of Public Health, 665 Huntington Ave., SPH-II, Rm. 221, Bos-
ton, MA 02115. Phone: (617) 432-2247; Fax: (617) 432-0014; email:
lkobzik@hsph.harvard.edu 
Scavenger Receptor MARCO and Lung Host Defense
 
268
 
Materials and Methods
 
Animals. 
 
8–12-wk-old male mice genetically deficient in
MARCO (MARCO
 
   
 
) were used in all experiments. Age- and
sex-matched wild-type (C57BL/6 MARCO
 
   
 
) mice pur-
chased from Charles River Laboratories were used as controls.
MARCO
 
   
 
 mice were developed using targeted homologous
recombination (unpublished data), and were backcrossed for at
least eight generations to the C57BL/6 background. All animals
were housed in sterile microisolator cages and had no evidence of
spontaneous infection. Approval before all experimentation was
obtained from the institutional animal use review committee.
 
Reagents and Particles. 
 
Titanium dioxide (TiO
 
2
 
) particles (me-
dian diameter 
 
 
 
1 
 
 
 
m) were provided by J. Brain (Harvard School
of Public Health, Boston, MA). Particles were suspended in BSS
 
 
 
(124 mM NaCl, 5.8 mM KCl, 10 mM dextrose, and 20 mM
Hepes) as stock solutions and sonicated 
 
 
 
30 s before use. All re-
agents not otherwise specified were obtained from Sigma-Aldrich.
 
Cell Isolation and Flow Cytometric Assay of Particulate Binding.
 
Mice were killed by i.p. pentobarbital injection. AMs obtained
by repeated lung lavage with BSS
 
 
 
 were centrifuged at 150 
 
g
 
 and
resuspended in BSS
 
 
 
 Ca (0.3 mM) and Mg (1 mM). AMs (2 
 
 
 
10
 
5
 
 in 100 
 
 
 
l BSS
 
 
 
) were preincubated with 2.5 
 
 
 
g/ml cytochal-
asin D for 5 min on ice in a 1-ml microfuge tube. After the addi-
tion of probe-sonicated particles, the tubes were rotated at 37
 
 
 
C
for 30 min, placed on ice, and analyzed by flow cytometry. Flow
cytometry was performed as described previously (15). AM up-
take of particles was measured using the increase in the mean
right angle scatter (RAS) caused by these granular materials (15).
 
Particle Effects In Vivo. 
 
Mice were lightly anesthetized with
halothane, and solutions of particles in pyrogen-free saline were
administered via intranasal insufflation (50 
 
 
 
L). Pilot experiments
in normal wild-type mice showed minimal response to 5 mg/ml
of the inert particle TiO
 
2
 
. These concentrations were used in
subsequent experiments comparing responses of MARCO-defi-
cient mice. Mice were killed 4 h later. Bronchoalveolar lavage
(BAL) was performed. Total cell yield was determined by
hemocytometer and differential by microscopic evaluation of cy-
tocentrifuge preparations stained with modified Wright-Giemsa.
Aliquots of cell-free BAL fluid were stored at 
 
 
 
70
 
 
 
C for the sub-
sequent ELISA assay of TNF-
 
 
 
 (R&D Systems). In some experi-
ments, whole lung tissue was harvested without lavage for RNA
extractions using the TRIzol reagent (GIBCO BRL). Expression
of a panel of cytokine mRNAs (lymphotoxin, RANTES, eo-
taxin, MIP-1b, MIP-1a, MIP-2, IP-10, MCP-1, and TCA-3)
was evaluated using a ribonuclease protection assay kit (mCK5;
BD Biosciences) following the manufacturer’s protocol. Blots
were visualized using an InstantImager™ Phosphoimager (Pack-
ard Instrument, Co.), and densitometric analysis was performed
using the dedicated Imager software package.
 
Bacteria. Streptococcus  pneumoniae
 
 serotype 3 was obtained
from the American Type Culture Collection and cultured
overnight on 5% sheep blood–supplemented agar Petri dishes
(VWR). A stock suspension was prepared, aliquoted in small vol-
umes, and kept at 
 
 
 
80
 
 
 
C. For each experiment, an aliquot was
grown overnight on a blood agar plate and resuspended in sterile
isotonic saline. Bacterial concentration of the obtained suspension
was estimated by OD
 
600
 
 measurements, and the appropriate dilu-
tion was prepared in saline to be administered intranasally to
mice. The true concentration was determined by culture.
 
Mouse Model of Pneumococcal Pneumonia. 
 
A well-character-
ized mouse model of pneumococcal pneumonia was used in this
analysis (19). Pneumonia was induced by intranasal instillation of
25 
 
 
 
l of a bacterial suspension containing 
 
 
 
10
 
5
 
 CFU of 
 
S. pneu-
moniae
 
 type 3 of mice under short-term anesthesia with hal-
othane. 4 or 24 h after infection, mice were killed with an i.p.
injection of a lethal dose of sodium pentobarbital (FatalPlus;
Vortech Pharmaceuticals). Separate experiments were performed
for either BAL and lung harvest for histology, or total lung bacte-
ria counts (CFU). At 4 or 24 h after infection, whole lungs were
harvested and homogenized in 1 ml of sterile isotonic saline with
a tissue homogenizer (Omni International). Serial 10-fold dilu-
tions in sterile saline were made from these homogenates, and
100 
 
 
 
l volumes were plated onto sheep-blood agar plates and in-
cubated at 37
 
 
 
C. CFUs were counted after 18–20 h. In some ex-
periments, to assess survival, mice were instilled intranasally with
a single 25-
 
 
 
l suspension of 
 
S. pneumoniae
 
 (
 
 
 
2 
 
 
 
 10
 
5
 
 CFU). An-
imal survival was monitored twice a day over a period of 12 d.
 
BAL. 
 
Animals were killed 4 or 24 h after bacterial chal-
lenge. BAL was performed in situ with a 20-gauge catheter in-
serted into the proximal trachea, flushing the lower airways five
times with 0.8 ml PBS. The fluid retrieved from the first flushing
was kept for ELISA assays. The BAL cells were separated from
the BAL fluid by centrifugation, resuspended in PBS, and
counted, and a fraction was cytospun on microscopic slides for
staining with Diff-Quick (Baxter Scientific Products) and for
subsequent differential counts.
 
Histopathology. 
 
Parallel infection experiments were per-
formed to harvest the lungs for histopathology. Age- and sex-
matched MARCO
 
   
 
 and MARCO
 
   
 
 control animals were
killed 24 h after inoculation. Lungs were harvested and kept in
10% formalin. Organs were examined histologically by hema-
toxylin and eosin staining. To quantitate AM number in situ,
nonspecific esterase staining of cryostat sections of normal lung
from wild-type or MARCO
 
   
 
 mice was performed. Random
fields of alveolar parenchyma were analyzed (10 per sample,
three mice per group). An index of esterase-positive macro-
phages (numerator) and alveolar tissue points (denominator)
were calculated using a grid projection system, and the data were
expressed as a ratio.
 
Preparation of FITC-labeled Pneumococci.  S.  pneumoniae
 
 were
labeled with FITC (Molecular Probes). Bacteria were grown
overnight on sheep blood agar plates, washed twice, and resus-
pended in PBS. Bacterial concentration was set to 
 
 
 
10
 
9
 
 CFU/ml
as determined by OD
 
600
 
. Bacteria were heat killed at 95
 
 
 
C for 10
min, centrifuged, and resuspended in 1 ml of labeling buffer
(0.1 M NaHCO
 
3
 
, pH 9.2). 0.25 mg of newly prepared FITC in
DMSO was added per milliliter of suspension, and bacteria were
incubated under constant stirring in the dark at room temperature
for 1 h. Bacteria were washed three times and dialyzed overnight
against PBS. Cell number was determined using a hemocytome-
ter under a fluorescence microscope. The final concentration was
set to 10
 
9
 
 bacteria/ml.
 
Phagocytosis Assay. 
 
Binding and phagocytosis of FITC-
labeled pneumococci by AMs were quantified using a flow cyto-
metric assay. BAL of MARCO
 
   
 
 and control mice was per-
formed in PBS, and cells were washed and resuspended in BSS
 
 
 
.
Aliquots of 0.5 ml (BAL cell count adjusted to 0.5 
 
 
 
 10
 
6
 
 cells/
ml, 
 
 
 
95% macrophages, as judged by differential staining) were
added to 1 ml conical microcentrifuge tubes together with FITC-
labeled pneumococci at a bacteria/AM ratio of 50:1, incubated
for 1 or 2 h at 37
 
 
 
C with continuous gentle rotation. Alterna-
tively, AMs were preincubated with 10 
 
 
 
M cytochalasin D
(Sigma-Aldrich) for 15 min at room temperature before the addi- 
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tion of bacteria. At the end of incubation, samples were washed
once with cold BSS
 
 
 
 to remove unbound bacteria and analyzed
for mean fluorescence intensity (MFI) of the macrophage popula-
tion by flow cytometry. The rate of phagocytosed bacteria was
calculated as the difference in fluorescence of untreated and cyto-
chalasin D–treated AMs.
 
Quantitation of BALF Cytokine Content by ELISA. 
 
MIP-2
and TNF-
 
 
 
 were quantitated in BALF of infected MARCO
 
   
 
and control mice using commercially available ELISA kits (R&D
Systems) following manufacturer’s instructions.
 
Statistical Analysis. 
 
Data were analyzed using the StatView
software (Abacus Concepts). Differences in survival were deter-
mined by 
 
 
 
2
 
 analysis. Kaplan-Meier curves were used to show
survival over time, and differences between curves were analyzed
using a log-rank test. For other measurements, differences be-
tween groups were examined by analysis of variance with correc-
tion for multiple groups. Data are presented as mean 
 
 
 
 SEM.
Results were considered significant when P 
 
 
 
 0.05.
 
Results and Discussion
 
First, we sought to investigate whether the absence of
MARCO receptor results in impaired bacterial clearance
from the lungs of infected mice. Mice were challenged by
intranasal administration of 
 
 
 
10
 
5
 
 CFU 
 
S. pneumonia,
 
 a rel-
atively low inoculum likely to be cleared by normal AMs
with minimal inflammation. Viable bacteria were quanti-
tated in lung tissue homogenates obtained after 4 h. Wild-
type MARCO
 
   
 
 mice showed efficient clearance of the
bacteria, with only 
 
 
 
8% of the inoculum being recovered
on average (Fig. 1 A). In contrast, 
 
 
 
50% of the inoculated
bacteria were still alive and recovered from the lungs of
MARCO
 
   
 
 mice (Fig. 1 A). Similar results were seen at
24 h after intranasal administration (Fig. 1 B).
BALF obtained 4 h after infection from MARCO
 
   
 
mice contained substantially more neutrophils compared
with 
 
   
 
 controls (Fig. 1, C and D, 17 
 
 
 
 7.40 vs. 2.45 
 
 
 
0.46%), a finding corroborated by histologic analysis of in-
fected lung tissue (Fig. 1, E and F). BAL fluid from infected
MARCO
 
   
 
 mice also contained higher amounts of TNF-
 
 
 
and MIP-2 (0.58 
 
 
 
 0.14 and 6.68 
 
 
 
 0.94 pg/ml, respec-
tively) than samples from control mice (Fig. 1 G, 0.13 
 
 
 
0.01 and 4.48 
 
 
 
 0.39 pg/ml, respectively). A similar profile
was observed 24 h after infection, though the overall levels
of cytokines were lower (Fig. 1 H). Morphometric com-
parison of the tissue density of macrophages showed no sig-
nificant differences between wild-type and MARCO
 
   
 
(1.027 
 
 
 
 0.034 vs. 1.077 
 
 
 
 0.028; mean 
 
 
 
 SEM; P 
 
 
 
0.29 
 
   
 
 vs. 
 
   
 
), a finding consistent with equal num-
bers of AMs recovered in BAL from normal MARCO
 
   
 
and MARCO
 
   
 
 mice (unpublished data). These data ex-
clude simple deficiency in numbers of AMs as the mecha-
nism for the differences observed in responses to bacteria
(or particles) in the MARCO
 
   
 
 mice.
A failure to eliminate 
 
S. pneumoniae reaching the bron-
choalveolar space may lead to increased mortality from se-
vere pneumonia or disseminated infection. To test this pos-
tulate, we investigated survival over time of MARCO   
and MARCO    mice inoculated with 2   105 CFU of
S. pneumoniae (a slightly higher dose required to detect
Figure 1. (A and B) Pulmo-
nary bacterial burden after infec-
tion with S. pneumoniae.
MARCO    and MARCO   
(n   7–9) were intranasally in-
fected with 105 CFU of S. pneu-
moniae. Lung bacterial load was
determined at 4 h (A) and 24 h
(B) after infection. Data shown
are representative of at least three
separate experiments, and pre-
sented as mean   SEM. *, P  
0.05 for     versus    . (C and
D) Lung inflammation in re-
sponse to S. pneumoniae infection.
PMN recruitment into BALF of
infected mice, harvested 4 h (C)
and 24 h (D) after infection, pre-
sented as percentage of total cells
in BALF. (E and F) Representa-
tive lung histology sections from
infected mice that showed
mostly normal histology in
MARCO    mice (E) and in-
creased focal PMN infiltrates in
MARCO    mice (F). (G and
H) Infected mice (n   4) BALF
TNF-  and MIP-2 at 4 h (G)
and 24 h (H) after infection as
measured by ELISA. Data are
presented as mean   SEM. *,
P   0.05 for     versus    .Scavenger Receptor MARCO and Lung Host Defense 270
mortality in the wild-type mice). Although mortality in the
wild-type group was 40%, the total mortality in the
MARCO    mice was 100% by day 10 (Fig. 2).
We postulate that these data correspond well to the nat-
ural history of pneumococcal infection in a nonimmune
host. Pneumococcal infection is relatively common, but far
less common than might be predicted from high rates of
nasopharyngeal colonization in normal adults and children
(20) and from the frequency of normal nocturnal aspiration
of upper airway secretions (21). Resident AMs are the most
important initial cellular defense against inhaled pathogens
(22, 23). Our data indicate that MARCO is a critical re-
ceptor for this early defense mechanism. Once established,
pneumococcal infection causes neutrophil influx in re-
sponse to unchecked bacterial proliferation and tissue in-
jury. In the absence of specific antibody, the PMN influx is
relatively ineffective in restricting progression of the pneu-
monia as evinced in the high mortality of untreated pneu-
mococcal pneumonia in people (24) and in the increased
mortality in MARCO    mice seen in survival studies.
To more directly evaluate the contribution of MARCO
receptor to AM binding and uptake of pneumococci, AMs
from wild-type and MARCO    mice were incubated for
1 h with FITC-labeled S. pneumoniae in the absence or
presence of cytochalasin D, and the samples were analyzed
by flow cytometry. In the presence of cytochalasin D, only
binding of fluorescent bacteria occurs because internal-
ization is blocked (15, 25). Under these conditions,
MARCO    AMs showed substantially diminished bacte-
rial binding (Fig. 3, e.g., 80 vs. 162 MFI units). When both
binding and internalization were intact (absence of cyto-
chalasin D), AMs from wild-type mice exhibited almost a
fourfold higher MFI value compared with the MARCO-
deficient mice AMs (Fig. 3, 323 vs. 90 MFI units). Calcula-
tion of the fluorescence attributable to internalization of
bacteria by AMs shows a substantially lower amount in
MARCO    mice (Fig. 2, inset, 161 vs. 10 MFI units).
These data are consistent with the marked defect in clear-
ance of bacteria and the resulting increased inflammatory
response observed in vivo.
Nevertheless, the persistence of some residual binding
indicates the presence of other receptors capable of binding
to S. pneumoniae. Interestingly, the absence of MARCO
also reduced internalization of the lower numbers of AM-
bound S. pneumoniae. The basis for this indirect implication
of MARCO in the internalization process for bound bacte-
ria is unclear and warrants further study.
Next, we investigated in vivo responses to a prototypical
“inert” particle (TiO2), so named because usually it is rap-
idly cleared by AM phagocytosis with minimal or no pul-
monary inflammation or injury (26, 27). BAL analysis 4 h
later showed diminished uptake of particles by AMs from
the MARCO    mice (Fig. 4 A). TiO2 administration
caused minimal PMN influx into BAL samples from wild-
type control mice (Fig. 4 B). In contrast, MARCO   
Figure 2. Absence of MARCO increases mortality after S. pneumoniae
administration to mice. MARCO    and MARCO    mice were intra-
nasally inoculated with 2.2   105 CFU of S. pneumoniae, and survival was
monitored over a period of 13 d. Data are expressed as percentage of mice
alive at each time point. Kaplan-Meier survival plots are shown for 10
animals per group. Mantel-Cox log-rank test showed that P   0.0342.
One experiment representative of two is shown.
Figure 3. Binding and phagocytosis of
FITC-labeled  S. pneumoniae (S.pn.) by
MARCO    and MARCO    AMs. AMs
were harvested from untreated mice, and
phagocytosis was measured as described in
Materials and Methods. Fluorescence was
measured on untreated cells (AM) and cells
incubated with labeled bacteria in the absence
(AM   S.pn.) or presence of cytochalasin D
(AM   S.pn.   CD) to block internalization.
The deduced phagocytosis rate as expressed
in MFI units is shown in the inset. Data
shown are representative of two experiments.Arredouani et al. Brief Definitive Report 271
mice showed a dramatic increase in PMN trafficking into
the lungs (102.8   39.8   103 cells/ml), compared with
the control mice (6.3   1.2   103 cells/ml) and to vehicle
(PBS)-induced recruitment in both groups (Fig. 4 B).
Analysis of BAL fluid from TiO2-treated MARCO   
mice also showed a marked increase of TNF-  (837   397
pg/ml), as compared with 100   50 pg/ml in response to
PBS (Fig. 4 C). In wild-type mice, the level of BALF
TNF-  induced by TiO2 (82   85 pg/ml) was low and
not different from the vehicle (PBS) control (84   20 pg/
ml). Analysis of cytokine mRNA expression using an
RNase protection assay (Fig. 4 D) showed that TiO2 chal-
lenge induced a higher rate of MIP-2 expression in the
lung tissue from MARCO    mice (relative increase after
TiO2 vs. PBS challenge, MARCO    vs. MARCO   ,
3.4   1.4 vs. 0.6   0.09).
To test the possibility that MARCO    AMs show an
altered cytokine response to TiO2, we measured TNF- 
and MIP-2 release by AMs treated in vitro with TiO2.
MARCO    and  /  AMs showed similar levels of in-
creased cytokine release in response to the positive control,
LPS, and similarly minimal release in response to TiO2 (un-
published data). Also, AMs lavaged from MARCO   
mice 2 h after instillation of TiO2 (before the large increase
of PMNs seen at 4 h) also did not show any substantial in-
crease in cytokine release after in vitro culture (unpublished
data). These findings argue against an altered response in
MARCO    AMs as the source of mediators seen after in
vivo TiO2.
The enhanced inflammatory response seen with inert
TiO2 in MARCO    mice is noteworthy. We postulate
that the reduced binding of TiO2 by MARCO    AMs (as
demonstrated in vivo; Fig. 4 A) allows increased interaction
of TiO2 with other lung cells (i.e., epithelium) due to de-
layed uptake by the AM, which in turn leads to the in-
creased MIP-2 expression and neutrophil influx observed.
In contrast with its lack of proinflammatory effects on
AMs, TiO2 has been shown to elicit release by lung epithe-
lial cells of chemokines for neutrophils such as MIP-2 and
other cytokines (28, 29).
These studies using MARCO-deficient mice show an
important function for this AM class A scavenger receptor
in host defense against pneumococcal pneumonia and
against pulmonary inflammation from otherwise inert envi-
ronmental dusts. Because SRA (including MARCO)
expression levels can increase or decrease in response to
various stimuli (30), the possibility that pathologic or thera-
peutic changes in MARCO expression might impact lung
host defense merits further investigation.
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